Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results, Meets Estimates

Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results, Meets Estimates

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) released its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $1.20 million during the quarter, compared to analysts' expectations of $1.63 million.

Lucid Diagnostics outlines commercial acceleration as Medicare pays $1,938.01 per EsoGuard test

Lucid Diagnostics says Medicare pays $1,938.01 per EsoGuard test; Q3 revenue was $1.2 million and October test volume set a record.

Lucid Diagnostics Records More Than 1,800 EsoGuard Tests in October

October volume set a monthly record as Lucid outlined nationwide access through individual Medicare claim reviews.

Lucid Diagnostics (NASDAQ:LUCD) Releases Earnings Results, Hits Expectations

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06), FiscalAI reports. The firm had revenue of $1.20 million during the quarter, compared to analyst estimates of $1.63 million. Here are the key takeaways from […]

Lucid Diagnostics reports US$1.2M EsoGuard revenue

Lucid Diagnostics reported US$1.2 million in quarterly EsoGuard revenue and US$18 million in cash before a subsequent US$15 million financing.